Abbott Laboratories (NYSE:ABT) Shares Sold by Inspirion Wealth Advisors LLC

Inspirion Wealth Advisors LLC reduced its position in Abbott Laboratories (NYSE:ABT - Free Report) by 1.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 187,998 shares of the healthcare product maker's stock after selling 3,295 shares during the quarter. Abbott Laboratories makes up about 3.0% of Inspirion Wealth Advisors LLC's holdings, making the stock its 12th largest position. Inspirion Wealth Advisors LLC's holdings in Abbott Laboratories were worth $21,319,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Insight Folios Inc increased its position in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock valued at $307,000 after purchasing an additional 87 shares during the last quarter. Sfmg LLC increased its position in Abbott Laboratories by 1.9% during the third quarter. Sfmg LLC now owns 4,622 shares of the healthcare product maker's stock valued at $527,000 after acquiring an additional 88 shares during the last quarter. Boltwood Capital Management raised its stake in shares of Abbott Laboratories by 0.4% in the third quarter. Boltwood Capital Management now owns 21,821 shares of the healthcare product maker's stock valued at $2,488,000 after acquiring an additional 89 shares during the period. Wedge Capital Management L L P NC boosted its stake in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after purchasing an additional 89 shares during the period. Finally, Silicon Valley Capital Partners grew its holdings in Abbott Laboratories by 8.7% during the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after purchasing an additional 89 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 0.4 %

ABT stock traded down $0.46 during trading on Friday, reaching $113.45. 6,443,213 shares of the company traded hands, compared to its average volume of 5,077,783. The business has a 50 day simple moving average of $115.00 and a 200 day simple moving average of $112.66. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64. The company has a market capitalization of $196.78 billion, a price-to-earnings ratio of 34.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, January 15th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 2.08%. Abbott Laboratories's dividend payout ratio (DPR) is 66.87%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Raymond James reaffirmed a "buy" rating and set a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Royal Bank of Canada lifted their target price on Abbott Laboratories from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. Morgan Stanley upped their price target on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an "equal weight" rating in a report on Thursday, October 17th. Piper Sandler lifted their price objective on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, October 17th. Finally, Piper Sandler Companies started coverage on shares of Abbott Laboratories in a research note on Thursday, September 19th. They issued an "overweight" rating and a $131.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.57.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.